Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

Treatment of Thrombocytopenia with Recombinant Human Thrombopoietin Combined Recombinant Human Interleukin 11

Xiao Rong;Jiang Tao;Department of Hematology,Sichuan Provincial People's Hospital;Sichuan Academy of Medical Sciences;  
Objective This study aimed to analyze the effect of recombinant human thrombopoietin and recombinant human interleukin 11 in thrombocytopenia. Methods A total of 70 patients with thrombocytopenia in our hospital from October 2016. to November 2018, were divided into the control group and the experimental group, with 35 cases in each group. The control group was treated with recombinant human interleukin 11 and the experimental group was treated with recombinant human thrombopoietin. The effects of the two treatment regimens on platelet-related indicators, incidence of adverse reactions, changes in T lymphocyte subsets, and total effective rate of treatment were compared. Results Compared with the control group, the platelet-related index and T lymphocyte subsets were superior in the experimental group(P0.05). The incidence of adverse reactions was lower than that in the control group(P0.05); the total effective rate of treatment compared with the control group, the experimental group was higher, statistically significant(P0.05). Conclusion Thrombocytopenia has certain clinical effects with recombinant human thrombopoietin and recombinant human interleukin-11, but recombinant human thrombopoietin is superior to recombinant human interleukin 11, especially in platelet-related indicators and T. Lymphocyte subsets have certain advantages, and have fewer adverse reactions and higher safety, which is worthy of clinical application.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved